With the ESMO 2016 just around the corner, we've selected some sessions of interest for journalists attending the congress
The full ESMO 2016 Press Programme will be available mid-September.
80 late-breaking abstracts submitted
Top submissions are in the fields of colorectal and gastrointestinal cancers, non-small-cell lung cancer, genitourinary tumours and immunotherapy.
These must-attend sessions will give delegates the full picture regarding the evolution of cancer research and patient care, reaching beyond individual disease types to offer thought-provoking interdisciplinary discussion including:
- The development of checkpoint inhibitors by Jim Allison, Saturday, 8 October, 13:00
- The art of the possible: Bridging the gap between genomics and patient care? by Emile Voest, Sunday, 9 October, 13:00
- The patient journey: Is cancer cure around the corner? by Jean-Charles Soria, Monday, 10 October, 13:00
A fully-dedicated track with more than 100 abstracts submitted, including hands-on educational sessions for practitioners, with a focus on patient selection and side-effect management.
Other programme highlights include:
- Record number of abstracts submitted under the Biomarkers topic, highlighting the importance of patient selection in treatment efficacy from the early phases of drug development to the bedside.
- Spotlight on resistance to therapy, the use of mouse models to help develop better targeted therapies and adapting clinical trials to tumour biology.
- The latest on BRCA testing in ovarian cancer and triple-negative breast cancer.
- Challenges and promises in the treatment of tumours of the central nervous system.
- How to provide patients with precision medicine in the clinic – interdisciplinary patient cases to translate theory into reality.
- A “Drugs you will be using in 2020” special symposium to share a vision of what to expect in the years ahead.
- Cancer prevention and screening including evidence-based prevention approaches.
- Public policy: sessions focusing on the most important public policy issues including the equitable delivery of anti-cancer drugs, the registration and use of Big Data and individual molecular profiles, and different approaches to qualify clinical benefit in oncology.